RSS

Sanofi Genzyme

Cablivi (caplacizumab) has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for the treatment of a rare blood-clotting disorder, acquired thrombotic thrombocytopenic purpura (aTTP) more

News

Bill Sibold has been appointed as executive vice president of Sanofi Genzyme with effect from 1 July. In this role, he will also be a member of the executive committee. more

News